Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Proteomic and Glycomic Markers to Differentiate Lung Adenocarcinoma from COPD

Author(s): Miklós Szabó, László Hajba, Renáta Kun, András Guttman* and Eszter Csánky

Volume 27, Issue 20, 2020

Page: [3302 - 3313] Pages: 12

DOI: 10.2174/0929867325666181017112939

Price: $65

Abstract

Lung adenocarcinoma is one of the leading causes of mortality among cancer patients worldwide and Chronic Obstructive Pulmonary Disease (COPD) is also high in death statistics. In addition, patients with Chronic Obstructive Pulmonary Disease (COPD) have a high risk of developing primary lung cancer. Prevention, risk estimation and a non-invasive diagnostics are essential to decrease COPD and lung cancer mortality. Therefore, better and more accurate molecular diagnostic markers (biomarkers) are needed for the early differential diagnosis of these lung diseases to help clinicians make better therapeutic decisions. This review focuses on recently discovered adenocarcinoma and COPD biomarkers at the proteome and glycome level. In the first part, the protein markers are summarized, while the second part is focused on glycan markers. Their use to differentiate between chronic inflammation (COPD) and malignant (adenocarcinoma) diseases is discussed in detail.

Keywords: Lung cancer, lung adenocarcinoma, COPD, molecular markers, proteomics, glycomics.

« Previous Next »
[1]
Cancer Research UK Lung cancer mortality statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/mortality (January 3, 2014).
[2]
Sholl, L.M. Biomarkers in lung adenocarcinoma: a decade of progress. Arch. Pathol. Lab. Med., 2015, 139(4), 469-480.
[http://dx.doi.org/10.5858/arpa.2014-0128-RA] [PMID: 25255293]
[3]
Bittner, N.; Ostoros, G.; Géczi, L. New treatment options for lung adenocarcinoma--in view of molecular background. Pathol. Oncol. Res., 2014, 20(1), 11-25.
[http://dx.doi.org/10.1007/s12253-013-9719-9] [PMID: 24306880]
[4]
Mo Ahn, J.; Yoel Cho, J. Current serum lung cancer biomarkers. J. Mol. Bio. Diag, 2013, s4, 1
[5]
American Cancer Society https://www.cancer.org/ cancer/lung-cancer.html (2016)
[6]
Lu, A.; Zhang, L. Tumor-dependent and -independent serum/plasma biomarkers for early diagnosis of lung cancer. Transl. Med. (Sunnyvale), 2016, 06(01)1000160
[http://dx.doi.org/10.4172/2161-1025.1000160]
[7]
Ostoros, G. In Korányi Bulletin; National Korányi Pulmonology Institute: Budapest, 2018, Vol. 1, pp. 30-38.http://www.koranyi.hu/tartalom/bulletin/Evkonyv2018.pdf
[8]
Zamay, T.N.; Zamay, G.S.; Kolovskaya, O.S.; Zukov, R.A.; Petrova, M.M.; Gargaun, A.; Berezovski, M.V.; Kichkailo, A.S. Current and prospective protein biomarkers of lung cancer. Cancers (Basel), 2017, 9(11), 155.
[http://dx.doi.org/10.3390/cancers9110155] [PMID: 29137182]
[9]
Shoshan-Barmatz, V.; Bishitz, Y.; Paul, A.; Krelin, Y.; Nakdimon, I.; Peled, N.; Lavon, A.; Rudoy-Zilberman, E.; Refaely, Y. A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma. Oncotarget, 2017, 8(62), 105492-105509.
[http://dx.doi.org/10.18632/oncotarget.22298] [PMID: 29285267]
[10]
Postmus, P.E.; Kerr, K.M.; Oudkerk, M.; Senan, S.; Waller, D.A.; Vansteenkiste, J.; Escriu, C.; Peters, S.; Committee, E.G. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol, 2017, 28(suppl_4), iv1-iv21.
[11]
Smith, J.J.; Berg, C.D. Lung cancer screening: promise and pitfalls. Semin. Oncol. Nurs., 2008, 24(1), 9-15.
[http://dx.doi.org/10.1016/j.soncn.2007.11.007] [PMID: 18222147]
[12]
Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M.; Sicks, J.D.; Team, N.L.S.T.R. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 2011, 365(5), 395-409.
[http://dx.doi.org/10.1056/NEJMoa1102873] [PMID: 21714641]
[13]
Veronesi, G.; Maisonneuve, P.; Bellomi, M.; Rampinelli, C.; Durli, I.; Bertolotti, R.; Spaggiari, L. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann. Intern. Med., 2012, 157(11), 776-784.
[http://dx.doi.org/10.7326/0003-4819-157-11-201212040-00005] [PMID: 23208167]
[14]
Bigbee, W.L.; Gopalakrishnan, V.; Weissfeld, J.L.; Wilson, D.O.; Dacic, S.; Lokshin, A.E.; Siegfried, J.M. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J. Thorac. Oncol., 2012, 7(4), 698-708.
[http://dx.doi.org/10.1097/JTO.0b013e31824ab6b0] [PMID: 22425918]
[15]
Rennard, S.I.; Drummond, M.B. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet, 2015, 385(9979), 1778-1788.
[http://dx.doi.org/10.1016/S0140-6736(15)60647-X] [PMID: 25943942]
[16]
Buist, A.S.; McBurnie, M.A.; Vollmer, W.M.; Gillespie, S.; Burney, P.; Mannino, D.M.; Menezes, A.M.; Sullivan, S.D.; Lee, T.A.; Weiss, K.B.; Jensen, R.L.; Marks, G.B.; Gulsvik, A.; Nizankowska-Mogilnicka, E.; Group, B.C.R. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 2007, 370(9589), 741-750.
[http://dx.doi.org/10.1016/S0140-6736(07)61377-4] [PMID: 17765523]
[17]
Ferré, A.; Fuhrman, C.; Zureik, M.; Chouaid, C.; Vergnenègre, A.; Huchon, G.; Delmas, M.C.; Roche, N. Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions. Respir. Med., 2012, 106(3), 467-471.
[http://dx.doi.org/10.1016/j.rmed.2011.12.002] [PMID: 22197577]
[18]
Halbert, R.J.; Natoli, J.L.; Gano, A.; Badamgarav, E.; Buist, A.S.; Mannino, D.M. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J., 2006, 28(3), 523-532.
[http://dx.doi.org/10.1183/09031936.06.00124605] [PMID: 16611654]
[19]
Braido, F.; Bagnasco, D.; Scichilone, N.; Santus, P.; Solidoro, P.; Di Marco, F.; Corsico, A.; Canonica, G.W. Biomarkers in obstructive respiratory diseases: an update. Panminerva Med., 2012, 54(2), 119-127.
[PMID: 22525566]
[20]
Liu, Y.; Pleasants, R.A.; Croft, J.B.; Wheaton, A.G.; Heidari, K.; Malarcher, A.M.; Ohar, J.A.; Kraft, M.; Mannino, D.M.; Strange, C. Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10, 1409-1416.
[http://dx.doi.org/10.2147/COPD.S82259] [PMID: 26229460]
[21]
Houghton, A.M. Mechanistic links between COPD and lung cancer. Nat. Rev. Cancer, 2013, 13(4), 233-245.
[http://dx.doi.org/10.1038/nrc3477] [PMID: 23467302]
[22]
Raviv, S.; Hawkins, K.A.; DeCamp, M.M., Jr; Kalhan, R. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. Am. J. Respir. Crit. Care Med., 2011, 183(9), 1138-1146.
[http://dx.doi.org/10.1164/rccm.201008-1274CI] [PMID: 21177883]
[23]
Durham, A.L.; Adcock, I.M. The relationship between COPD and lung cancer. Lung Cancer, 2015, 90(2), 121-127.
[http://dx.doi.org/10.1016/j.lungcan.2015.08.017] [PMID: 26363803]
[24]
Indovina, P.; Marcelli, E.; Maranta, P.; Tarro, G. Lung cancer proteomics: recent advances in biomarker discovery. Int. J. Proteomics, 2011, 2011
[http://dx.doi.org/10.1155/2011/726869] [PMID: 22229091]
[25]
Pastor, M.D.; Nogal, A.; Molina-Pinelo, S.; Quintanal-Villalonga, Á.; Meléndez, R.; Ferrer, I.; Romero-Romero, B.; De Miguel, M.J.; López-Campos, J.L.; Corral, J.; García-Carboner, R.; Carnero, A.; Paz-Ares, L. IL-11 and CCL-1: Novel protein diagnostic biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid (BALF). J. Thorac. Oncol., 2016, 11(12), 2183-2192.
[http://dx.doi.org/10.1016/j.jtho.2016.07.026] [PMID: 27524264]
[26]
Bhatnagar, S.; Katare, D.P.; Jain, S.K. Serum-based protein biomarkers for detection of lung cancer. Cent. Eur. J. Biol., 2014, 9(4), 341-358.
[http://dx.doi.org/10.2478/s11535-013-0271-0]
[27]
Nalejska, E.; Mączyńska, E.; Lewandowska, M.A. Prognostic and predictive biomarkers: tools in personalized oncology. Mol. Diagn. Ther., 2014, 18(3), 273-284.
[http://dx.doi.org/10.1007/s40291-013-0077-9] [PMID: 24385403]
[28]
Chung, K.; Nishiyama, N.; Yamano, S.; Komatsu, H.; Hanada, S.; Wei, M.; Wanibuchi, H.; Suehiro, S.; Kakehashi, A. Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma. Cancer Biomark., 2012, 10(2), 101-107.
[http://dx.doi.org/10.3233/CBM-2012-0234] [PMID: 22430137]
[29]
Jin, H.; Dai, Z.N.; Jin, C.L.; Hong, J.; Ze-ning, D.; Chun-lan, J. Discrimination analysis of mass spectrometry proteomics for lung adenocarcinoma detection. Labmedicine, 2011, 42(6), 344-349.
[http://dx.doi.org/10.1309/LMXWEJV3FFDR0DHH]
[30]
Yang, L.; Che, Y.; Guo, L.; Zheng, B.; Wang, B.; Yang, Z.; Zhu, Y.; Li, J. Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China. Thorac. Cancer, 2018, 9(4), 439-444.
[http://dx.doi.org/10.1111/1759-7714.12595] [PMID: 29400000]
[31]
Li, W.; Zheng, H.; Qin, H.; Liu, G.; Ke, L.; Li, Y.; Li, N.; Zhong, X. Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ-coupled 2D LC-MS/MS. Clin. Respir. J., 2018, 12(6), 2036-2045.
[http://dx.doi.org/10.1111/crj.12771] [PMID: 29363881]
[32]
Liu, Z.; Gao, Y.; Hao, F.; Lou, X.; Zhang, X.; Li, Y.; Wu, D.; Xiao, T.; Yang, L.; Li, Q.; Qiu, X.; Wang, E. Secretomes are a potential source of molecular targets for cancer therapies and indicate that APOE is a candidate biomarker for lung adenocarcinoma metastasis. Mol. Biol. Rep., 2014, 41(11), 7507-7523.
[http://dx.doi.org/10.1007/s11033-014-3641-4] [PMID: 25098600]
[33]
Almatroodi, S.A.; McDonald, C.F.; Collins, A.L.; Darby, I.A.; Pouniotis, D.S. Quantitative proteomics of bronchoalveolar lavage fluid in lung adenocarcinoma. Cancer Genomics Proteomics, 2015, 12(1), 39-48.
[PMID: 25560643]
[34]
Jiang, M.; Gu, G.; Ni, B.; Wang, W.; Shi, J.; Liao, P.; Hu, H. Detection of serum protein biomarkers by surface enhanced laser desorption/ionization in patients with adenocarcinoma of the lung. Asia Pac. J. Clin. Oncol., 2014, 10(2), e7-e12.
[http://dx.doi.org/10.1111/ajco.12057] [PMID: 23441957]
[35]
Ortea, I.; Rodríguez-Ariza, A.; Chicano-Gálvez, E.; Arenas Vacas, M.S.; Jurado Gámez, B. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J. Proteomics, 2016, 138, 106-114.
[http://dx.doi.org/10.1016/j.jprot.2016.02.010] [PMID: 26917472]
[36]
Sheng, S.H.; Zhu, H.L. Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy. Clin. Transl. Oncol., 2014, 16(2), 153-157.
[http://dx.doi.org/10.1007/s12094-013-1054-9] [PMID: 23907289]
[37]
Vykoukal, J.; Sun, N.; Aguilar-Bonavides, C.; Katayama, H.; Tanaka, I.; Fahrmann, J.F.; Capello, M.; Fujimoto, J.; Aguilar, M.; Wistuba, I.I.; Taguchi, A.; Ostrin, E.J.; Hanash, S.M. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget, 2017, 8(56), 95466-95480.
[http://dx.doi.org/10.18632/oncotarget.20748] [PMID: 29221141]
[38]
Zhou, X.; Xue, L.; Hao, L.; Liu, S.; Zhou, F.; Xiong, H.; Qi, X.; Lin, D.; Shao, S. Proteomics-based identification of tumor relevant proteins in lung adenocarcinoma. Biomed. Pharmacother., 2013, 67(7), 621-627.
[http://dx.doi.org/10.1016/j.biopha.2013.06.005] [PMID: 23916545]
[39]
Lai, T.W.; Wu, D.; Chen, M.; Cao, C.; Jing, Z.L.; Huang, L.; Lv, Y.Y.; Zhao, X.N.; Lv, Q.C.; Wang, Y.J.; Li, D.M.; Wu, B.; Shen, H.H. YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling; Resp Res, 2016, p. 17.
[40]
Minas, M.; Mystridou, P.; Georgoulias, P.; Pournaras, S.; Kostikas, K.; Gourgoulianis, K.I. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD, 2013, 10(1), 28-34.
[http://dx.doi.org/10.3109/15412555.2012.727922] [PMID: 23272665]
[41]
Johansson, S.L.; Roberts, N.B.; Schlosser, A.; Andersen, C.B.; Carlsen, J.; Wulf-Johansson, H.; Sækmose, S.G.; Titlestad, I.L.; Tornoe, I.; Miller, B.; Tal-Singer, R.; Holmskov, U.; Vestbo, J.; Sorensen, G.L. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respir. Med., 2014, 108(9), 1336-1344.
[http://dx.doi.org/10.1016/j.rmed.2014.06.003] [PMID: 25022422]
[42]
Merali, S.; Barrero, C.A.; Bowler, R.P.; Chen, D.E.; Criner, G.; Braverman, A.; Litwin, S.; Yeung, A.; Kelsen, S.G. Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling. COPD, 2014, 11(2), 177-189.
[http://dx.doi.org/10.3109/15412555.2013.831063] [PMID: 24111704]
[43]
Vagulienė, N.; Žemaitis, M.; Miliauskas, S.; Urbonienė, D.; Šitkauskienė, B.; Sakalauskas, R. Comparison of C-reactive protein levels in patients with lung cancer and chronic obstructive pulmonary disease. Medicina (Kaunas), 2011, 47(8), 421-427.
[http://dx.doi.org/10.3390/medicina47080059] [PMID: 22123552]
[44]
Balla, M.M.S.; Desai, S.; Purwar, P.; Kumar, A.; Bhandarkar, P.; Shejul, Y.K.; Pramesh, C.S.; Laskar, S.; Pandey, B.N. Differential diagnosis of lung cancer, its metastasis and chronic obstructive pulmonary disease based on serum Vegf, Il-8 and MMP-9. Sci. Rep., 2016, 6, 36065.
[http://dx.doi.org/10.1038/srep36065] [PMID: 27811960]
[45]
Sin, D.D.; Tammemagi, C.M.; Lam, S.; Barnett, M.J.; Duan, X.; Tam, A.; Auman, H.; Feng, Z.; Goodman, G.E.; Hanash, S.; Taguchi, A. Pro-surfactant protein B as a biomarker for lung cancer prediction. J. Clin. Oncol., 2013, 31(36), 4536-4543.
[http://dx.doi.org/10.1200/JCO.2013.50.6105] [PMID: 24248694]
[46]
Chu, Y.; Lai, Y.H.; Lee, M.C.; Yeh, Y.J.; Wu, Y.K.; Tsao, W.; Huang, C.Y.; Wu, S. Calsyntenin-1, clusterin and neutrophil gelatinase-associated lipocalin are candidate serological biomarkers for lung adenocarcinoma. Oncotarget, 2017, 8(64), 107964-107976.
[http://dx.doi.org/10.18632/oncotarget.22438] [PMID: 29296216]
[47]
Li, X.; Che, K.; Wang, L.; Zhang, T.; Wang, G.; Pang, Z.; Shen, H.; Du, J. Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma. Medicine (Baltimore), 2017, 96(45) e8450
[http://dx.doi.org/10.1097/MD.0000000000008450] [PMID: 29137031]
[48]
Li, Y.; Cao, Z.Y.; Sun, B.; Wang, G.Y.; Fu, Z.; Liu, Y.M.; Kong, Q.F.; Wang, J.H.; Zhang, Y.; Xu, X.Y.; Li, H.L. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol. Ther., 2011, 12(7), 610-616.
[http://dx.doi.org/10.4161/cbt.12.7.16302] [PMID: 21785272]
[49]
Hokka, D.; Maniwa, Y.; Tane, S.; Nishio, W.; Yoshimura, M.; Okita, Y.; Ohbayashi, C.; Sakai, Y.; Chen, X.; Hayashi, Y. Psf3 is a prognostic biomarker in lung adenocarcinoma. Lung Cancer, 2013, 79(1), 77-82.
[http://dx.doi.org/10.1016/j.lungcan.2012.10.001] [PMID: 23127337]
[50]
Takada, K.; Okamoto, T.; Shoji, F.; Shimokawa, M.; Akamine, T.; Takamori, S.; Katsura, M.; Suzuki, Y.; Fujishita, T.; Toyokawa, G.; Morodomi, Y.; Okano, S.; Oda, Y.; Maehara, Y. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J. Thorac. Oncol., 2016, 11(11), 1879-1890.
[http://dx.doi.org/10.1016/j.jtho.2016.06.006] [PMID: 27346415]
[51]
Wiedl, T.; Arni, S.; Roschitzki, B.; Grossmann, J.; Collaud, S.; Soltermann, A.; Hillinger, S.; Aebersold, R.; Weder, W. Activity-based proteomics: identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. J. Proteomics, 2011, 74(10), 1884-1894.
[http://dx.doi.org/10.1016/j.jprot.2011.04.030] [PMID: 21596165]
[52]
Zhou, W.; Ma, H.; Deng, G.; Tang, L.; Lu, J.; Chen, X. Clinical significance and biological function of fucosyltransferase 2 in lung adenocarcinoma. Oncotarget, 2017, 8(57), 97246-97259.
[http://dx.doi.org/10.18632/oncotarget.21896] [PMID: 29228607]
[53]
Ju, C.R.; Liu, W.; Chen, R.C. Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease. Dis. Markers, 2012, 32(5), 281-287.
[http://dx.doi.org/10.1155/2012/509063] [PMID: 22674408]
[54]
Jaswal, S.; Saini, V.; Kaur, J.; Gupta, S. Evaluation of circulating protein biomarkers of inflammation in COPD. J. Med. Sci. Clin. Res., 2017, 5(04), 20202-20206.
[http://dx.doi.org/10.18535/jmscr/v5i4.75]
[55]
Xia, J.; Zhao, J.; Shang, J.; Li, M.; Zeng, Z.; Zhao, J.; Wang, J.; Xu, Y.; Xie, J. Increased IL-33 expression in chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol., 2015, 308(7), L619-L627.
[http://dx.doi.org/10.1152/ajplung.00305.2014] [PMID: 25595648]
[56]
Silva, D.R.; Gazzana, M.B.; Knorst, M.M. C-reactive protein levels in stable COPD patients: a case-control study. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10, 1719-1725.
[http://dx.doi.org/10.2147/COPD.S87015] [PMID: 26357470]
[57]
Kurt, O.K.; Tosun, M.; Kurt, E.B.; Talay, F. Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation, 2015, 38(1), 89-93.
[http://dx.doi.org/10.1007/s10753-014-0010-3] [PMID: 25303877]
[58]
El-Deek, S.E.; Makhlouf, H.A.; Saleem, T.H.; Mandour, M.A.; Mohamed, N.A.; Surfactant Protein, D. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med. Princ. Pract., 2013, 22(5), 469-474.
[http://dx.doi.org/10.1159/000349934] [PMID: 23860258]
[59]
Lee, K.Y.; Chuang, H.C.; Chen, T.T.; Liu, W.T.; Su, C.L.; Feng, P.H.; Chiang, L.L.; Bien, M.Y.; Ho, S.C. Proteoglycan 4 is a diagnostic biomarker for COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, 10, 1999-2007.
[PMID: 26451097]
[60]
Zhang, M.; Zhang, J.; Zhang, Q.; Yang, X.; Shan, H.; Ming, Z.; Chen, H.; Liu, Y.; Yin, J.; Li, Y. D-dimer as a potential biomarker for the progression of COPD. Clin. Chim. Acta, 2016, 455, 55-59.
[http://dx.doi.org/10.1016/j.cca.2016.01.024] [PMID: 26826394]
[61]
Pastor, M.D.; Nogal, A.; Molina-Pinelo, S.; Meléndez, R.; Salinas, A.; González De la Peña, M.; Martín-Juan, J.; Corral, J.; García-Carbonero, R.; Carnero, A.; Paz-Ares, L. Identification of proteomic signatures associated with lung cancer and COPD. J. Proteomics, 2013, 89, 227-237.
[http://dx.doi.org/10.1016/j.jprot.2013.04.037] [PMID: 23665002]
[62]
Varki, A.; Cummings, R.; Esko, J.; Freeze, H.; Stanley, P.; Bertozzi, C.; Hart, G.W.; Etzler, M. Essentials of Glycobiology, 2nd ed; Cold Spring Harbor Laboratory Press: Plainview, NY, 2009.
[63]
Lemjabbar-Alaoui, H.; McKinney, A.; Yang, Y.W.; Tran, V.M.; Phillips, J.J. Glycosylation alterations in lung and brain cancer. Adv. Cancer Res., 2015, 126, 305-344.
[http://dx.doi.org/10.1016/bs.acr.2014.11.007] [PMID: 25727152]
[64]
Arnold, J.N.; Saldova, R.; Galligan, M.C.; Murphy, T.B.; Mimura-Kimura, Y.; Telford, J.E.; Godwin, A.K.; Rudd, P.M. Novel glycan biomarkers for the detection of lung cancer. J. Proteome Res., 2011, 10(4), 1755-1764.
[http://dx.doi.org/10.1021/pr101034t] [PMID: 21214223]
[65]
Bartling, B.; Vanhooren, V.; Dewaele, S.; Libert, C.; Hofmann, H.S.; Haerting, J.; Nuding, S.; Silber, R.E.; Simm, A.; Chen, C.C. Altered desialylated plasma N-glycan profile in patients with non-small cell lung carcinoma. Cancer Biomark., 2011-2012-2012, 10(3-4), 145-154.,
[http://dx.doi.org/10.3233/CBM-2012-0239] [PMID: 22674300]
[66]
Ruhaak, L.R.; Nguyen, U.T.; Stroble, C.; Taylor, S.L.; Taguchi, A.; Hanash, S.M.; Lebrilla, C.B.; Kim, K.; Miyamoto, S. Enrichment strategies in glycomics-based lung cancer biomarker development. Proteomics Clin. Appl., 2013, 7(9-10), 664-676.
[http://dx.doi.org/10.1002/prca.201200131] [PMID: 23640812]
[67]
Liang, Y.; Ma, T.; Thakur, A.; Yu, H.; Gao, L.; Shi, P.; Li, X.; Ren, H.; Jia, L.; Zhang, S.; Li, Z.; Chen, M. Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology, 2015, 25(3), 331-340.
[http://dx.doi.org/10.1093/glycob/cwu115] [PMID: 25347993]
[68]
Ruhaak, L.R.; Taylor, S.L.; Stroble, C.; Nguyen, U.T.; Parker, E.A.; Song, T.; Lebrilla, C.B.; Rom, W.N.; Pass, H.; Kim, K.; Kelly, K.; Miyamoto, S. Differential N-glycosylation patterns in lung adenocarcinoma tissue. J. Proteome Res., 2015, 14(11), 4538-4549.
[http://dx.doi.org/10.1021/acs.jproteome.5b00255] [PMID: 26322380]
[69]
Wang, X.; Deng, Z.; Huang, C.; Zhu, T.; Lou, J.; Wang, L.; Li, Y. Differential N-glycan patterns identified in lung adenocarcinoma by N-glycan profiling of formalin-fixed paraffin-embedded (FFPE) tissue sections. J. Proteomics, 2018, 172, 1-10.
[http://dx.doi.org/10.1016/j.jprot.2017.11.010] [PMID: 29157724]
[70]
Gao, C.; Taniguchi, N. Sugar Chains: Decoding the Functions of Glycans; Suzuki, T.; Ohtsubo, K.; Taniguchi, N; Japan, S., Ed.; Tokyo, 2015, pp. 259-266.
[http://dx.doi.org/10.1007/978-4-431-55381-6_16]
[71]
Angata, T.; Fujinawa, R.; Kurimoto, A.; Nakajima, K.; Kato, M.; Takamatsu, S.; Korekane, H.; Gao, C.X.; Ohtsubo, K.; Kitazume, S.; Taniguchi, N. Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Ann. N. Y. Acad. Sci., 2012, 1253, 159-169.
[http://dx.doi.org/10.1111/j.1749-6632.2012.06469.x] [PMID: 22380786]
[72]
Ito, E.; Oka, R.; Ishii, T.; Korekane, H.; Kurimoto, A.; Kizuka, Y.; Kitazume, S.; Ariki, S.; Takahashi, M.; Kuroki, Y.; Kida, K.; Taniguchi, N. Fucosylated surfactant protein-D is a biomarker candidate for the development of chronic obstructive pulmonary disease. J. Proteomics, , 2015, 127(Pt B), 386-394.,
[http://dx.doi.org/10.1016/j.jprot.2015.07.011]
[73]
Váradi, C.; Mittermayr, S.; Szekrényes, Á.; Kádas, J.; Takacs, L.; Kurucz, I.; Guttman, A. Analysis of haptoglobin N-glycome alterations in inflammatory and malignant lung diseases by capillary electrophoresis. Electrophoresis, 2013, 34(16), 2287-2294.
[http://dx.doi.org/10.1002/elps.201300041] [PMID: 23580236]

Rights & Permissions Print Cite
Article Metrics
37
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy